Cachexia: A Review of Therapeutic and Management
Article Sidebar
Main Article Content
Abstract
Chronically ill patients going through treatment have a tendency to experience complications associated to either their illnesses or therapy. Evolution in health care can improve treatment outcome if the patient could tolerate therapeutic interventions. Supportive care is described as any measure that makes patient more tolerable to the treatment and consequently improves quality of life. Recently, the definition of supportive care has been expanded to embrace the time of diagnosis to the end of patients’ life, even when the illness is cured. This broader description has encouraged the pharmacists in to implement pharmaceutical care as some of treatment complications take long time to resolve such as effect on reproduction, endocrine function, etc. Cachexia is a chronic complication often identified in chronically ill patients and associated increased morbidity and mortality. This article emphasizes on pharmacotherapeutic management and supportive care aspect of cachexia.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5’-tri-phosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000;92(4):321-8.
Akamizu T, Kangawa K. Ghrelin for cachexia. J Cachex Sarcopenia Muscle 2010;1(2):169-76.
Berenstein EG, Ortiz Z. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Syst Rev 2005;CD004310.
Carroll DN, Roth MT. Evidence for the cardioprotective effects of omega-3 fatty acids [abstract]. Ann Pharmacother 2002;36(12):1950-6.
Clark RH, Feleke G, Din M, et al. Nutritional treatment for acquired immunodeficiency virus-associat-ed wasting using β-hydroxy-β-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study [abstract]. J Parenter Enteral Nutr 2000;24:133–9.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on defini-tion and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39(4):412-23.
Dewey A, Baughan C, Dean TP, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database of Syst Rev 2007:CD004597.
Dodson S, Baracos VE, Jatoi A, et al. Muscle wast-ing in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies.Annu Rev Med 2011;62:265–79.
Downer S, Joel S, Allbright A, et al. A double blindplacebo controlled trial of medroxyprogester-one acetate (MPA) in cancer cachexia. Br J Cancer 1993;67(5):1102-5.
Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008;27(6):793-9.
Evans WJ. Skeletal muscle loss: cachexia, sar-copenia, and inactivity. Am J Clin Nutr 2010;91(4):1123S-1127S.
Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52(10):1479-86.
Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998;55(5):675-88.
Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol 2003;1:194-205.
Gordon JN, Trebble TM, Ellis RD, et al. Thalido-mide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005;54(4):540-5.
Inui A. Cancer anorexia-cachexia syndrome: current is-sues in research and management. CA Cancer J Clin 2002;52(2):72-91.
Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapen-taenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22(12):2469-76.
Kardinal CG, Loprinzi CL, Schaid DJ, et al. A control-led trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65(12):2657-62.
Kotler DP. Cachexia. Ann Intern Med 2000;133:622-34.
Lai V, George J, Richey L. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008;30(1):67-74.
López AP, Figuls MR, Cuchi GG. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004;27(4):360-9.
Lundholm K, Gelin J, Hyltander A, et al. Anti-inflamma-tory treatment may prolong survival in under-nourished patient with metastatic solid tumors. Cancer Res 1994;54:5602–6.
Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer 2010; 18:1-9.
Muscaritoli M, Anker SD, Argilés J, et al. Consensusdefinition of sarcopenia, cachexia andpre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nu-trition in geriatrics”.Clin Nutr 2010;29(2):154-9.
Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83(4):735-43.Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128(3):1187-93.
Navari R, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010;18:951–6.
Niu Q, Li T, Liu A. Cytokines in experimental cancer cachexia [abstract]. Zhonghua Zhong Liu Za Zhi 2001;23(5):382-4.
Radbruch L, Elsner F, Trottenberg P, et al. Clinical practice guidelines on cancer cachexia in advanced cancer patients. Aachen: Department of Palliative Medicinen/European Palliative Care Research Collaborative; 2010.
Schambelan M, Mulligan K, Grunfeld C, et al.Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 1996;125(11):873-82.
Smith HJ, Greenberg NA, Tisdale MJ. Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice. Br J Cancer 2004;91(2):408-12.
Steinborn W, Anker SD. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myol 2003;13(4):191-201.
Tisdale MJ. Clinical anticachexia treatments. Nutr Clin Pract 2006;21(2):168-74.
Topkan E, Yavuz AA, Ozyilkan O. Cancer cachexia: pathophysiologic aspects and treatment option. Asian Pac J Cancer Prev 2007;8(3):445-51.
Tramontana JM, Utaipat U, Molloy A. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1(4):384-97.
Wadleigh R, Spalding GM, Lumbersky B, et al. Dronabinol enhancement of appetite and cancer patients [abstract]. Proc Am Soc Oncol 1990;9:331.
Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008;31:492–501.
Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72(1):185-8.
Yavuzsen T, Davis MP, Walsh D,et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23(33):8500-11.
Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine 2006;1(4):411-6.
Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet 2007;369:1090-8.